Avita Medical (ASX:AVH) share price jumps on FDA approval

Avita shares have landed in the green from the market open. Here are the details…

| More on:
A group of science or medical professionals cheering good news in the lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Avita Medical Inc (ASX: AVH) share price is in the green in early afternoon trade. Avita shares are on the move after the company gained regulatory momentum overnight.

Let's discuss further.

A quick refresher on Avita Medical

Avita Medical is a medical technology company that has expertise in regenerative medicine. Its flagship product is the revolutionary Recell system, used to help skin recover from burns.

In addition, Avita is trialling Recell on other domains such as soft tissue reconstruction and paediatric scald injuries.

At the time of writing, Avita Medical has a market capitalisation of $587 million.

What did Avita announce?

In a positive for the Avitia Medical share price, the company has realised some regulatory tailwinds overnight.

To illustrate, in an announcement Avita advised that the US Food and Drug Administration (FDA) approved the company's request to amend its pivotal clinical trial investigating Recell's application in vitiligo lesions.

Vitiligo is an autoimmune condition that results in the loss of pigmentation of skin.

Recall that Avita originally sought the "strategic decision" to amend its formulation "based on data from other research efforts".

Avita's decision effectively restructures and simplifies the study design. Therefore, the company can progress the program "in a timely and cost-effective manner".

Moreover, the program "is on track" and Avita is confident it could have Recell available for vitiligo applications "as early as the second half of calendar year 2023".

In addition, the new "single-arm" study design allows 23 subjects at 15 sites to be evaluated. This is in contrast to the previous, 3-arm study of 84 patients.

Based on "other research efforts" mentioned above, Avita understands the "1:20 expansion ratio" is the best regime in this application as it used the "least amount of donor skin".

Speaking on the release, Avita chief executive Dr Mike Perry said:

The design change allows this program to progress in a timely and cost-effective manner toward bringing a novel therapeutic option to an underserved population. Our ongoing multi-media outreach and clinical and advocacy group referral programs are generating significant interest in the trial.

Avita Medical share price snapshot

The Avita Medical share price has jumped following the announcement, landing in the green in midday trade. To illustrate, Avita shares are now exchanging hands at $4.76 apiece, a 0.85% jump from the open.

The Avita Medical share price has posted a loss of more than 3% this year to date, and 25% in the past 12 months.

These results have lagged the S&P/ASX 200 Index (ASX: XJO)'s return of around 25% over the past year.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Rising gold share price represented by a green arrow on piles of gold block.
Share Gainers

2 ASX All Ords stocks that would already have more than doubled your money this year

These ASX All Ords stocks have gained 126% and 145% year to date. But how?

Read more »

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was an historic day for the ASX, with the market setting a new record.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Fletcher Building, Johns Lyng, Pilbara Minerals, and Zip shares are charging higher

These shares are having a strong session on hump day. But why?

Read more »

A cool dude looks back at the camera while ziplining above the treetops.
BNPL shares

Zip share price rockets 19% on full-year earnings upgrade

Surging again today, Zip shares are now up 127% since their recent April lows.

Read more »

happy teenager using iPhone
Share Gainers

Up 96% since April, should I still buy Life360 shares today?

A leading expert offers his verdict on the growth outlook for the surging Life360 share price.

Read more »

Businessman smiles with arms outstretched after receiving good news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a lucrative return to trading for investors this Tuesday.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Austal, Botanix, DroneShield, and NextDC shares are storming higher today

These shares are starting the week with a bang. But why?

Read more »

A female coal miner wearing a white hardhat and orange high-vis vest holds a lump of coal and smiles as the Whitehaven Coal share price rises today
Share Gainers

The Coronado Global share price just surged to a 114% weekly gain. Here's why

Investors have sent the ASX coal stock flying higher in June. But why?

Read more »